Roche CEO says new drugs will offset biosimilar incursions
ZURICH: Swiss drugmaker Roche will be able to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals’ copies through its new medicines, Chief Executive Severin Schwan said.
Schwan’s outlook, delivered to shareholders at the company’s annual general meeting in Basel, confirms Roche’s previous guidance that 2018 sales will be flat or grow by a low-single-digit percentage compared to last year, amid incursions from so-called biosimilar drugs.
(Reporting by John Miller)
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd